Rank |
Status |
Study |
1 |
Not yet recruiting
|
Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study
Conditions: |
Healthy; Human; Adult; Parturient |
Interventions: |
Drug: Hydromorphone 25mcg; Drug: Hydromorphone 50mcg; Drug: Hydromorphone 100mcg; Drug: Hydromorphone 200mcg |
Outcome Measures: |
24hr post-partum IV opioid requirement; Oxygen saturation, need for supplemental oxygen; Nausea and vomiting requiring rescue medication; Hypothermia (body temperature < 95F/35C); Visual disturbances; Pruritus; Intraoperative vasopressor use |
|
2 |
Recruiting
|
Study of Respiratory Depression When Using a Hydromorphone Pain Protocol
Conditions: |
Pain; Respiratory Depression |
Interventions: |
Drug: Hydromorphone; Drug: Usual care group |
Outcome Measures: |
Respiratory Depression; Successful treatment of patient pain; Change in VAS score; Hypoxia; Hypotension; Allergic reaction to study drug; Serious Adverse Events |
|
3 |
Recruiting
|
Association Between Body Size and Response to Hydromorphone in ED
Condition: |
Pain |
Intervention: |
Drug: Hydromorphone |
Outcome Measures: |
Association between pain scale change and TBW/BMI; Association between change in pain at 15 minutes,; pain treatment satisfaction at 30 min; adverse events (low SatO2<92%, SBP< 90mmHg); side effects (nausea, vomit, itching); influence of gender on the association between TBW, BMI and response to iv hydromorphone; influence of race/ethnicity, and genetic factors on the association between TBW, BMI and response to iv hydromorphone; influence of genetic factors on the association between TBW, BMI and response to iv hydromorphone; influence of age on the association between TBW/BMI and response to hydromorphone |
|
4 |
Not yet recruiting
|
Intrathecal Hydromorphone for Pain Control After Cesarean Section
Conditions: |
Pain; Cesarean Section |
Interventions: |
Drug: Intrathecal morphine; Drug: Intrathecal hydromorphone |
Outcome Measures: |
Post operative fentanyl PCA consumption; Time to initial PCA use; Pain score; Patient satisfaction score; Side effects |
|
5 |
Recruiting
|
Titration of Intravenous Hydromorphone
Condition: |
Acute Severe Pain |
Intervention: |
Drug: Hydromorphone |
Outcome Measure: |
Frequency of different patterns of opioid request |
|
6 |
Recruiting
|
Methadone and Hydromorphone For Spinal Surgery
Conditions: |
Hydromorphone Use; Acute Postoperative Pain; Patient Satisfaction; Chronic Persistent Surgical Pain |
Interventions: |
Drug: Methadone; Drug: Hydromorphone |
Outcome Measures: |
Hydromorphone use at 24 hours; Hydromorphone use second 24 hours; Hydromorphone use third 24 hours; Pain scores postanesthesia care unit (PACU) arrival; Pain scores 1 hour after PACU arrival; Pain scores 2 hours after PACU arrival; Pain scores 4 hours after PACU arrival; Pain scores on postoperative day one; Pain scores on postoperative day 2; Pain scores postoperative day 3; Patient satisfaction scores; Chronic persistent surgical pain |
|
7 |
Recruiting
|
Safety and Efficacy Study of Hydromorphone HCl by Intrathecal Administration Using a Programmable Implantable Pump
Condition: |
Management of Chronic Pain |
Intervention: |
Drug: Hydromorphone Hydrochloride |
Outcome Measures: |
Superiority of intrathecal hydromorphone hydrochloride as compared to a control arm.; Functionality based on a Brief Pain Inventory |
|
8 |
Recruiting
|
Single-arm Study to Assess the Safety of Hydromorphone HCl by Intrathecal Administration
Condition: |
Chronic Pain |
Intervention: |
Drug: Hydromorphone Hydrochloride |
Outcome Measure: |
Frequency of Adverse Events during a 12-month period of treatment with intrathecal hydromorphone. |
|
9 |
Unknown †
|
Safety and Efficacy of Intravenous Hydromorphone in Elderly Emergency Department Patients With Acute Severe Pain
Condition: |
Pain |
Interventions: |
Drug: Hydromorphone; Drug: Usual care |
Outcome Measure: |
Proportion with successful treatment |
|
10 |
Recruiting
|
Intrathecal Hydromorphone for Cesarean Section
Condition: |
Pain |
Intervention: |
Drug: intrathecal hydromorphone (IT hydromorphone) |
Outcome Measures: |
The primary objective is to find the optimal dose of IT hydromorphone for pain relief following C/S.; A secondary objective is to define the incidence and severity of hydromorphone's side effects.; A secondary objective is to determine the duration of analgesia |
|
11 |
Recruiting
|
Fentanyl for Breakthrough Pain in the Emergency Department
Condition: |
Pain |
Interventions: |
Drug: Fentanyl Nasal Spray; Drug: Hydromorphone PCA; Other: Placebo Nasal Spray |
Outcome Measure: |
Total Pain Relief Score |
|
12 |
Recruiting
|
Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries
Condition: |
Pain |
Interventions: |
Drug: Hydromorphone; Drug: Morphine |
Outcome Measures: |
Change in Pain Scores; Number of Participants with Adverse Events (AEs) |
|
13 |
Recruiting
|
True Functional Restoration and Analgesia in Non-Radicular Low Back Pain
Condition: |
Low Back Pain |
Intervention: |
Drug: Hydromorphone ER |
Outcome Measures: |
The efficacy of Exalgo (hydromorphone HCl extended release) in Chronic Non-Radicular Low Back Pain (CNRBP) model syndrome to improve pain, function and activity; The relationship between pain ratings and functioning |
|
14 |
Recruiting
|
Intrathecal Opioids for Pain Control After Cesarean Delivery: Determining the Optimal Dose
Conditions: |
Analgesia, Obstetrical; Cesarean Section |
Interventions: |
Drug: Morphine; Drug: Hydromorphone |
Outcome Measures: |
Visual analog pain score following spinal anesthesia administration; Total opioid medication consumption; Visual analog pain score following administration of spinal anesthesia; Side effects: Pruritus; Side effects: Nausea; Side effects: Sedation |
|
15 |
Recruiting
|
Multiple Dose Study of Blockade of Opioid Effects of Subcutaneous Injections of Buprenorphine in Participants With Opioid Use Disorder
Condition: |
Opioid Use Disorder |
Interventions: |
Drug: Buprenorphine; Drug: buprenorphine and naloxone; Drug: hydromorphone; Drug: placebo |
Outcome Measures: |
Opioid Blockade Following Administration of 0, 6, or 18 mg Intramuscular (IM) Hydromorphone As Measured Using the Subjective Opioid Effects Rating for the Question "Do you like the drug?" Visual Analog Scale (VAS); Reinforcing Effects Of the Daily Randomized Hydromorphone Challenge as Measured by the Mean Hydromorphone Break Point Value; Relationship between plasma concentration and predicted mu opioid receptor occupancy of buprenorphine and both the blockade of the subjective effects of hydromorphone post injection of buprenorphine 300 mg (RBP-6000); Summary of Participants with Adverse Events; Correlation between the opioid blockade subjective effect when participants are asked "Do you feel any drug effect?" and simulated mu opioid receptor occupancy; Correlation between the opioid blockade subjective effect when participants are asked "Does the drug have any good effects?" and simulated mu opioid receptor occupancy; Correlation between the opioid blockade subjective effect when participants are asked "Do you like the drug?" and simulated mu opioid receptor occupancy; Correlation between the opioid blockade subjective effect when participants are asked "Do you feel sedated?" and simulated mu opioid receptor occupancy; Correlation between the opioid blockade subjective effect when participants are asked "How high are you right now?" and simulated mu opioid receptor occupancy; Correlation between the opioid blockade subjective effect when participants are asked "Does the drug have any bad effects?" and simulated mu opioid receptor occupancy |
|
16 |
Recruiting
|
Postoperative Pain Therapy With Hydromorphone Using TCI-PCA
Condition: |
Postoperative Pain |
Intervention: |
Drug: Hydromorphone |
Outcome Measures: |
Hydromorphone Plasma Concentrations; Numerical Rating Score |
|
17 |
Unknown †
|
Trial Comparing Morphine to Hydromorphone in Elderly Patients With Severe Pain
Condition: |
Acute Pain |
Interventions: |
Drug: Morphine 0.05 mg/kg Intravenous; Drug: Hydromorphone 0.0075 mg/kg intravenous |
Outcome Measures: |
The between-group difference in before-after improvement in pain scores measured 30 minutes after medications are infused.; Pain score comparisons at 15 minutes and 120 minutes; Total mg of additional pain medications required after initial medication; Pain relief measurement; Patient satisfaction measurement; Comparison of adverse events |
|
18 |
Recruiting
|
Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance
Conditions: |
Opioid Dependence; Pain; Addiction |
Interventions: |
Drug: Placebo; Drug: Hydromorphone; Drug: Buprenorphine |
Outcome Measures: |
Cold pressor test.; Innocuous stimulation.; Pressure pain.; Thermal pain.; Temporal summation.; Diffuse noxious inhibitory controls (DNIC).; Visual analog scales (VAS) of subjective drug effects.; Pupil diameter.; Number of participants with adverse events.; Profile of Mood States.; Vital Signs.; Trait pain catastrophizing.; Situational pain catastrophizing. |
|
19 |
Unknown †
|
Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone
Condition: |
Acute Pain |
Interventions: |
Drug: H2O; Drug: 1+1 |
Outcome Measures: |
Decline additional pain medication; Number of participants with hypotension (SBP < 90 mmHg); Number of participants with bradycardia (HR < 50/min); Number of patients with nausea and vomiting; Number of participants with pruritus; Number of participants needing naloxone as a reversal agent |
|
20 |
Recruiting
|
Epidural Analgesia Versus IV Analgesia in Lumbar Spine Fusions
Conditions: |
Lumbar Spine Fusion; Pain; Back Pain |
Interventions: |
Other: Epidural Catheter - Dilaudid; Drug: Dilaudid |
Outcome Measures: |
Post-operative pain as assessed by Visual Analogue Scale; Assessing change in patient functional status with regards to depression, anxiety, and pain; Patient satisfaction with peri-operative care; Patient satisfaction with perioperative analgesia; Number of participants with adverse events |
|